Author | Günther Köhler, MD, PhD


Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

April 01, 1997

ByHans-Joachim Lück, MD|Andreas Du Bois, MD, PhD|Christoph Thomssen, MD, PhD|Björn Lisboa, MD, PhD|Michael Untch, MD, PhD|Günther Köhler, MD, PhD|Detlev Hecker, PhD|Klaus Diergarten, MD

Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in